Bills · H.R. 10857 · Text
Introduced in House
Confirmed from the official record
Our copy of the file on govinfo.gov, saved November 13, 2026. Fingerprint (SHA-256): 8c4409ad7c8c4538.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 10857 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 10857
To amend the Federal Food, Drug, and Cosmetic Act and the Public Health
Service Act to advance the next-generation of clinical development of
novel treatments and cures, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
October 22, 2026
Mr. Auchincloss (for himself and Mr. Griffith) introduced the following
bill; which was referred to the Committee on Energy and Commerce, and
in addition to the Committee on Ways and Means, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act and the Public Health
Service Act to advance the next-generation of clinical development of
novel treatments and cures, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
(a) Short Title.--This Act may be cited as the ``Faster Clinical
Trials Act''.
(b) Table of Contents.--The table of contents for this Act is as
follows:
Sec. 1. Short title; table of contents.
TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE
Sec. 101. Cures in Care Initiative.
Sec. 102. Cures in Care Initiative lead network grant program.
Sec. 103. Cures in Care Initiative Collaborative.
Sec. 104. Definitions for Cures in Care Initiative and related
activities.
Sec. 105. Data standards with respect to data sharing.
Sec. 106. Clinical trial oversight modernization.
Sec. 107. Updates to patient costs and payment for participation in
clinical trials.
TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT
Sec. 201. Modernized evidence generation through new approach
methodologies.
Sec. 202. Modernized phase 1 clinical trial oversight.
Sec. 203. Global regulatory alignment to modernize clinical
development.
Sec. 204. Minimum United States representation in clinical trials.
Sec. 205. Food and Drug Administration Rare Disease Innovation Hub.
TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT
INNOVATION
Sec. 301. Resolving clinical holds and improving clinical trial
efficiency.
Sec. 302. Mutual recognition of GMP standards.
Sec. 303. Pathway for competitive generic therapies.
Sec. 304. Biosimilar biological products.
Sec. 305. Certification of patent information in certain applications
for biological products.
Sec. 306. GAO report.
Sec. 307. Definitions.
TITLE IV--PRECISION ONCOLOGY MODERNIZATION
Sec. 401. Findings and purpose.
Sec. 402. Oncology Center of Excellence.
Sec. 403. Labeling revisions for genomic exclusions in oncology drugs.
TITLE V--AMERICAN FRONTIER BIOBANK
Sec. 501. Establishment of the American Frontier Biobank.
TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE
SEC. 101. CURES IN CARE INITIATIVE.
(a) In General.--Part J of title IV of the Public Health Service
Act (42 U.S.C. 290c et seq.) is amended by adding at the end the
following:
``SEC. 499B. CURES IN CARE INITIATIVE ESTABLISHMENT.
``(a) Center for Clinical Trial Innovation.--The Secretary shall
establish the Center for Clinical Trial Innovation (in this section
referred to as the `Center') within the Center for Drug Evaluation and
Research of the Food and Drug Administration to carry out the
Initiative established under subsection (b), to be headed by a
director.
``(b) Establishment of Cures in Care Initiative.--
``(1) In general.--The Secretary, acting through the
Assistant Secretary of Health shall continue a Cures in Care
Initiative (in this section referred to as the `Initiative') to
expand, enhance, and promote routine point-of-care clinical
trials, including through the establishment and support of
broad-based clinical trial networks (in this section referred
to as a `lead network'), for the purpose of accelerating the
development of new treatments and cures by generating clinical
evidence faster and through novel methods.
``(2) Coordination and implementation.--The Assistant
Secretary of Health shall coordinate the activities of the
Commissioner of Food and Drugs and the Director of the National
Institutes of Health in implementing the Initiative.
``(3) Principal office.--The Secretary shall establish the
Center for Clinical Trial Innovation (in this section referred
to as the `Center') within the Center for Drug Evaluation and
Research of the Food and Drug Administration to serve as the
principal implementing office supporting the Assistant
Secretary of Health in carrying out the Initiative established
under subsection (a), to be headed by a director.
``(c) Duties.--In carrying out the Initiative, the Director shall--
``(1) identify priority disease or mechanism areas for the
purpose of implementing lead networks;
``(2) establish lead networks for each such a priority
disease or mechanism area by building on existing clinical
trial networks and infrastructures;
``(3) ensure each such network prioritizes the
participation of less-resourced clinical trial settings;
``(4) ensure each such network focuses on not less than--
``(A) 1 high-burden chronic disease; and
``(B) 1 group of rare diseases that are related or
similar to each other;
``(5) designate a central institutional review board to
review any routine point-of-care clinical trial carried out by
a lead network pursuant to this subsection;
``(6) coordinate actions carried out under the Initiative
for purposes of addressing barriers to the conduct of routine
point-of-care clinical trials carried out by a lead network
pursuant to this subsection, with respect to--
``(A) shared or central institutional review board
oversight;
``(B) patient consent, including electronic
consent;
``(C) alignment of health information technology
interoperability standards adopted by the Office of the
National Coordinator for Health Information Technology,
program data requirements administered by the Centers
for Medicare & Medicaid Services and the real-world
data standards maintained by the Commissioner of Food
and Drugs, consistent with applicable privacy and
confidentiality protections;
``(D) development of innovative clinical trial
methods;
``(E) publication transparency and reproducibility;
``(F) digital tools and artificial intelligence to
reduce the cost and burden of such clinical trials;
``(G) necessary infrastructure to implement a
decentralized clinical trial network, in a hub-and-
spoke model; and
``(H) governance of such clinical trials at
multiple sites;
``(7) establish an Food and Drug Administration-endorsed
clinical trial site certification program; and
``(8) in consultation with the Director of the National
Center for Advancing Translational Sciences award grants and
enter into contracts, cooperative agreements, and other
transactions, including as authorized under sections 499A(g)
and 499C.
``(d) Rapid Implementation.--The Director shall--
``(1) establish not less than 3 lead networks under
subsection (c) not later than 1 year after the date of
enactment of this subsection; and
``(2) upon establishment of such lead networks, develop the
plan described in subsection (e).
``(e) Implementation Plan for Expanding Activities.--
``(1) In general.--Not later than 3 years after the date of
enactment of this subsection, the Director shall implement a
comprehensive implementation plan describing how the Initiative
will broadly extend covered activities to the public and
private development of medical products, including stretch
goals with timeframes for--
``(A) achieving expanded patient access and site
access to routine point-of-care clinical trials,
including ensuring patient access at 60 percent of
health care delivery sites and for 90 percent of
eligible patients that participate in a clinical trial
carried out by a lead network established under
subsection (c);
``(B) reducing the cost of such a clinical trial,
including approaching a 30 to 50 percent reduction in
cost per patient and a 30 percent reduction in accrual
time;
``(C) enhancing any impact of such a clinical
trial, including ensuring that 90 percent of patients
participating in such a clinical trial obtain a timely,
independently reviewed, and publicly reported result;
and
``(D) assessing if lead networks are improving
trial execution, including site activation timelines,
time to first patient enrolled, enrollment and
retention performance, data quality, monitoring burden,
technology and workflow readiness, and the long-term
research readiness of participating sites.
``(2) Publication.--Not later than 3 years after the date
of enactment of this paragraph, the Director shall make
available to the public on the website of the Department of
Health and Human Services the implementation plan implemented
under paragraph (1).
``(3) Covered activity defined.--For purposes of paragraph
(1), the term `covered activity' means--
``(A) identifying priority disease or mechanism
areas under subsection (c) for the purpose of
implementing broad-based point-of-care clinical trial
networks; or
``(B) establishing a lead network under such
subsection for each such priority disease or mechanism
area.
``(f) Collaboration and Consultation.--
``(1) Required collaboration and consultation.--In carrying
out the Initiative, the Director shall collaborate and consult
with--
``(A) the Administrator of the Centers for Medicare
& Medicaid Services;
``(B) the Director of the Advanced Research
Projects Agency-Health;
``(C) the Administrator of the Health Resources and
Services Administration;
``(D) the Office of the National Coordinator for
Health Information Technology;
``(E) the Director of the Center for Biologics
Evaluation and Research;
``(F) the Office of the Assistant Secretary of
Health; and
``(G) representatives from--
``(i) health care organizations in a lead
network;
``(ii) network users, including researchers
and clinical trial administrators;
``(iii) provider groups that do not
directly collaborate with lead networks,
including health systems, academic medical
centers, and specialty medical societies;
``(iv) private and nonprofit organizations
funding such organizations and groups;
``(v) patient advocacy organizations;
``(vi) contract research organizations;
``(vii) technology partners; and
``(viii) such other partner organizations
as the Director determines appropriate.
``(2) Additional collaboration and consultation.--In
addition to the collaboration and consultation required under
paragraph (1), the Director may, as appropriate, collaborate
and consult with--
``(A) the Secretary of Veterans Affairs; and
``(B) the Secretary of Defense, including the
Director of the Defense Health Agency.
``(g) Training and Technical Assistance.--
``(1) In general.--In carrying out the Initiative, the
Director, in consultation with the Director of the National
Center for Advancing Translational Sciences, shall provide
training and technical assistance to--
``(A) a lead network established under subsection
(c);
``(B) a health care organization or other partner
organization seeking to participate in a routine point-
of-care clinical trial carried out by a lead network;
``(C) any entity that applies for a grant,
cooperative agreement, contract, or other transaction
under section 499C but does not receive such grant,
cooperative agreement, contract, or other transaction;
and
``(D) an emerging biotechnology company.
``(2) Contents.--In providing training and technical
assistance under paragraph (1), the Director may address
clinical development and regulatory subjects, including--
``(A) protocol development;
``(B) regulatory interactions with the Food and
Drug Administration;
``(C) data infrastructure integration;
``(D) sponsor and site engagement in designing,
conducting, and evaluating clinical trials;
``(E) sustainability planning; and
``(F) general public education on clinical trials
and their potential risks and benefits.
``(3) Format.--The Director shall make these training and
technical assistance materials available in an online resource
center, including resources on--
``(A) staff training materials;
``(B) trial-network participation;
``(C) technology support;
``(D) data quality assessments;
``(E) Institutional Review Board templates and best
practices;
``(F) study startup; and
``(G) capacity building.
``(4) Priority.--In carrying out this subsection, the
Director shall give priority to less-resourced clinical trial
settings.
``(5) Contracts and cooperative agreements for training.--
The Director may enter into contracts or cooperative agreements
with entities, such as the Reagan-Udall Foundation for the Food
and Drug Administration established under section 770 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd), to--
``(A) establish training programs; and
``(B) hold meetings for health care organizations,
clinical research organizations, technology partners,
and patient-led organizations participating in a lead
network established under subsection (c).
``(h) External Engagement.--The Commissioner of Food and Drugs
shall establish and expand the external engagement capacity of the
Center through the performance commitments under section 736B of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2).
``(i) FDA Guidance.--Not later than 18 months after the date of
enactment of this subsection, the Commissioner of Food and Drugs shall,
in consultation with the Director, issue any draft or final guidance as
may be necessary to carry out this section, including with respect to--
``(1) guidelines for carrying out routine point-of-care
clinical trial networks, including governance, data monitoring,
and application of an innovative clinical trial method, drawing
on existing Food and Drug Administration guidance for platform
studies;
``(2) any update to guidance on decentralized clinical
trials, remote monitoring of such trials, and real-world data
and real-world evidence; and
``(3) reliance on central institutional review boards and
electronic consent in routine point-of-care clinical trials.
``(j) Reports.--
``(1) Annual reports.--Not later than 1 year after the date
of enactment of this paragraph, and annually thereafter, the
Director shall submit to the Committee on Energy and Commerce
of the House of Representatives and the Committee on Health,
Education, Labor, and Pensions of the Senate, and make
available to the public on the website of the Department, a
report on, with respect to the period covered by the report,
the progress of the Initiative in advancing routine point-of-
care clinical trials, with respect to each priority disease or
mechanism area and lead network established under subsection
(c), including--
``(A) progress addressing any barrier described in
such subsection;
``(B) the availability and performance of any
routine point-of-care clinical trial in the United
States;
``(C) any trend in the United States with respect
to such clinical trials; and
``(D) the participation rate of less-resourced
clinical trial settings in each such lead network.
``(2) Evaluation reports.--
``(A) 3-year report.--Not later than 3 years after
the date of enactment of this subparagraph, the
Director shall submit to the Committee on Energy and
Commerce of the House of Representatives and the
Committee on Health, Education, Labor, and Pensions of
the Senate a report containing--
``(i) an evaluation of--
``(I) the outcome of any
coordination, collaboration, and
consultation required under this
section, including the performance of
each lead network established under
subsection (c);
``(II) any expanded patient access
and site access to routine point-of-
care clinical trials that is
attributable to the Initiative;
``(III) any improvement in the
participation rate of less-resourced
clinical trial settings that is
attributable to the Initiative;
``(IV) any improvement in the
participation rate of emerging
biotechnology sponsors within the lead
network; and
``(V) alignment of interagency
action under this section; and
``(ii) any recommendation for additional
legislative action to accelerate progress in
carrying out routine point-of-care clinical
trials and developing medical products.
``(B) 5-year report.--Not later than 5 years after
the date of enactment of this subparagraph, the
Director shall submit a report in such manner and
containing such information as required under
subparagraph (A).
``(k) Medical Product Defined.--In this section, the term `medical
product' means--
``(1) a drug or device, as defined in section 201 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or
``(2) a biological product, as defined in section 351 of
this Act.
``(l) Authorization of Appropriations.--In addition to any funds
made available in the FDA Innovation Account under section
1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-255) and
any amount made available under section 499C, there is authorized to be
appropriated to carry out this section $500,000,000 for each of fiscal
years 2027 through 2031, to remain available until expended.''.
(b) FDA Innovation Account.--
(1) Transfer of direct spending savings.--Section
1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-
255) is amended to read as follows:
``(A) In general.--The following amounts shall be
transferred to the Account from the general fund of the
Treasury:
``(i) For fiscal year 2027, $20,000,000.
``(ii) For fiscal year 2028, $60,000,000.
``(iii) For fiscal year 2029, $70,000,000.
``(iv) For fiscal year 2030, $75,000,000.
``(v) For fiscal year 2031, $70,000,000.''.
(2) Authorization of appropriations.--Section 1002(b)(3) of
the 21st Century Cures Act (Public Law 114-255) is amended by
striking ``2017 through 2025'' each place such term appears and
inserting ``2027 through 2031''.
(3) FDA activities.--Section 1002(b)(4) of the 21st Century
Cures Act (Public Law 114-255) is amended to read as follows:
``(4) FDA activities.--The activities authorized to be
funded under this section are the activities under--
``(A) section 507 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 357);
``(B) section 1014 of such Act (21 U.S.C. 399g);
and
``(C) section 499B of the Public Health Service
Act, as added by section 101(a) of the Faster Clinical
Trials Act.''.
(c) Conforming Amendment.--Part J of Title IV of the Public Health
Service (42 U.S.C. 290c et seq.) is further amended by striking
``advanced research projects agency-health'' in the part heading and
inserting ``advanced health research projects''.
SEC. 102. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.
Part J of title IV of the Public Health Service Act (42 U.S.C. 290c
et seq.) is amended by adding at the end the following:
``SEC. 499C. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.
``(a) In General.--Not later than 5 years after the date of
enactment of this subsection, the Commissioner of Food and Drugs, in
consultation with the Director of the Center for Clinical Trial
Innovation, and the Director of the National Institutes of Health,
acting through the Center for Advancing Translational Sciences and the
Advanced Research Projects Agency-Health, (in this section referred to
as the `Commissioner and Director') shall make grants to, or enter into
cooperative agreements, contracts, or other transactions with, not
fewer than 3 lead networks established under section 499B(c) to--
``(1) achieve not later than 3 years after the date on
which an appropriation is first made under subsection (e),
measurable improvements in the clinical evidence base for each
priority disease or mechanism area for which such network was
established; and
``(2) enable broader implementation of routine point-of-
care clinical trials beyond such lead network.
``(b) Use of Funds.--The Commissioner and Director may require a
lead network that receives a grant, or enters into a cooperative
agreement, contract, or other transaction, under this section to use
any funding received through such grant, cooperative agreement,
contract, or transaction to--
``(1) implement the data sharing standards described under
section 105 of the Faster Clinical Trials Act;
``(2) implement site data infrastructure and clinical
research technology;
``(3) leverage existing clinical trial networks, Federal
digital health and artificial intelligence initiatives, and
virtual participation options, consistent with good clinical
practice;
``(4) provide a plan for reliable collection and sharing of
data on covariates, treatments, outcomes, and adverse events
with respect to the applicable disease or mechanism area;
``(5) support, as appropriate--
``(A) phase 2 and 3 clinical trials;
``(B) label expansion studies;
``(C) comparative effectiveness studies; and
``(D) post-market commitments and phase 4
commitments;
``(6) include sites and patients from less-resourced
clinical trial settings;
``(7) include patients from populations not primarily
served by academic health centers;
``(8) include emerging biotechnology companies;
``(9) establish grants specifically for less-resourced
sites, including federally qualified health centers, to enable
participation;
``(10) collaborate or partner with multiple commercial
developers of medical products (as defined in section 499B)
that are active in the applicable disease or mechanism area;
and
``(11) include a plan for sustainability with respect to a
routine point-of-care clinical trial carried out by such
platform, including a description of--
``(A) any partial startup funding from a non-
Federal source;
``(B) an additional study on the common trial
platform to be carried out after the date on which the
period described in subsection (c) ends; and
``(C) an understanding of how lead networks will
maintain infrastructure and research beyond initial
Federal support, including long-term site readiness,
staffing and workforce support, technology maintenance,
continued community-site participation, sponsor
adoption and utilization, and the operational resources
necessary to support multiple studies over time.
``(c) Duration.--
``(1) In general.--Subject to paragraph (2), a grant,
cooperation agreement, contract, or other transaction under
this section shall be for a period of not more than 5 years.
``(2) Extension for material contribution.--The
Commissioner and Director may extend the 5-year period
described in paragraph (1) by not more than 3 years if the
Commissioner and Director determine that such extension will
materially contribute to fulfillment of the implementation plan
required under section 499B.
``(d) Evaluation.--
``(1) In general.--The Cures in Care Initiative
Collaborative established under section 499D shall evaluate any
activity carried out using any funds received through a grant,
cooperative agreement, contract, or transaction under this
section, including--
``(A) a partnership between a lead network and a
sponsor or health care organization that are additional
sites of care;
``(B) compared to traditional baselines, the cost
of--
``(i) recruiting, enrolling, and treating
each patient enrolled in a routine point-of-
care clinical trial; and
``(ii) completing each such trial;
``(C) any research impact such an activity has on--
``(i) such clinical trials;
``(ii) any site in which such a clinical
trial is performed; and
``(iii) any effect on the evidence base;
``(D) inclusion of less-resourced clinical trial
settings; and
``(E) any opportunity to increase scaling and
sustainability with respect to such a clinical trial
carried out by a lead network that receives such funds,
including--
``(i) a maintenance plan for clinical trial
sites to continue participating after the
initial grant period ends; and
``(ii) continued education for sites and
training opportunities for staff.
``(2) Publication.--Not later than 3 years after the date
of enactment of this paragraph, and annually thereafter, the
Collaborative shall make available to the public on the website
of the Department of Health and Human Services the evaluation
carried out under paragraph (1).
``(e) Budget Clarification; Agency Contributions.--
``(1) Authorization of appropriations.--There is authorized
to be appropriated to carry out this section such sums as
necessary for each of fiscal years 2027 through 2031, to remain
available until expended.
``(2) Common fund.--The Commissioner and Director may
reserve to carry out this section any amounts made available
under paragraph (1) for the Common Fund established under
section 402A(c)(1).
``(3) Budget clarification.--Any budget request of the
President shall specify an amount for carrying out this
section.
``(4) Agency contributions.--In addition to any funds made
available under section 402A(a)(3), the Secretary may transfer
funds from other departmental agencies and programs to carry
out the Initiative established under section 499B, including
the grant program established under this section, provided such
funds do not supplant funding under such section and such
transfer will further the authorized programs of the
contributing agency or program.''.
SEC. 103. CURES IN CARE INITIATIVE COLLABORATIVE.
Part J of title IV of the Public Health Service Act (42 U.S.C. 290c
et seq.) is amended by adding at the end the following:
``SEC. 499D. CURES IN CARE INITIATIVE COLLABORATIVE.
``(a) In General.--The Secretary, acting through the Director of
NIH and the Director of the Center for Clinical Trial Innovation, shall
establish, through entering into a contract, cooperative agreement,
memorandum of understanding, or other mechanism, a public-private
partnership, to be known as the Cures in Care Initiative Collaborative
(in this section referred to as the `Collaborative'), to--
``(1) promote routine point-of-care clinical trials,
including the development of novel trial methodologies;
``(2) promote the elimination of barriers to trial
initiation and completion; and
``(3) support lead networks under the Cures in Care
Initiative established under section 499B.
``(b) Required Activities.--The Collaborative shall--
``(1) establish user groups, workshops, and other forums
for sponsors, contract research organizations, health care
organizations, technology providers, patient organizations, and
Federal agencies to identify and address implementation
barriers to routine point-of-care clinical trials;
``(2) provide technical assistance, including on protocol
development, regulatory interactions, and data infrastructure,
to sponsors of routine point-of-care clinical trials and lead
networks that receive a grant, or enter into a cooperative
agreement, contract, or other transaction, under section 499C;
``(3) support sandbox testing of innovations in trial
design, data infrastructure, consent, and governance prior to
broader adoption of such innovations;
``(4) evaluate incentives to support and sustain site
participation in clinical trial networks;
``(5) maintain public reporting on progress, barriers, and
outcomes of routine point-of-care clinical trial innovation;
``(6) coordinate with--
``(A) existing public-private partnerships on
routine point-of-care clinical trial innovation;
``(B) existing research infrastructures within the
National Institutes of Health and the Advanced Research
Projects Agency-Health; and
``(C) the Center for Medicare and Medicaid
Innovation established under section 1115A of the
Social Security Act (42 U.S.C. 1315a), except that the
Collaborative may not direct, or be directed by, such
Center;
``(7) carry out the evaluation required under section
499C(d);
``(8) support practical technology and operational
enablement of lead networks, including development and testing
of integrated technology packages that can provide
participating sites with interoperable tools, standardized
workflows, training, implementation support, monitoring and
data quality capabilities, and centralized technical assistance
for less resourced sites; and
``(9) assess opportunities to centralize services,
including patient recruitment, to reduce the burden of
participation for clinical trial sites.
``(c) Federal Advisory Committee Act Applicability.--Chapter 10 of
title 5, United States Code, shall not apply to the Collaborative.''.
SEC. 104. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED
ACTIVITIES.
Part J of title IV of the Public Health Service Act (42 U.S.C. 290c
et seq.) is amended by adding at the end the following:
``SEC. 499E. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED
ACTIVITIES.
``In this part:
``(1) Clinical investigation.--The term `clinical
investigation' has the meaning given such term in section 50.3
of title 21, Code of Federal Regulations (or any successor
regulation).
``(2) Innovative clinical trial method.--The term
`innovative clinical trial method' includes adaptive,
decentralized, Bayesian, platform, and external-control trial
designs, as such terms are described in guidance issued by the
Food and Drug Administration, including pursuant to section
3021 of the 21st Century Cures Act (21 U.S.C. 355 note) and
section 3606 of the Consolidated Appropriations Act, 2023 (21
U.S.C. 360a-1 note).
``(3) Lead disease or mechanism area.--The term `lead
disease or mechanism area' means a disease, condition, or
disease-mechanism area that presents substantial opportunity
for scaled, reusable platforms for routine point-of-care
clinical trials.
``(4) Lead network.--The term `lead network' means a
network of participating health care organizations for a lead
disease or mechanism area.
``(5) Less-resourced clinical trial setting.--The term
`less-resourced clinical trial setting' means a health care
organization or provider that--
``(A) is located in, or primarily serves, a
medically underserved community (as defined in section
799B(6) of this Act); or
``(B) is--
``(i) a Federally qualified health center
(as defined in section 1861 of the Social
Security Act (42 U.S.C. 1395x));
``(ii) a rural health clinic (as defined in
such section);
``(iii) a critical access hospital (as
defined in such section);
``(iv) a health center that, during the
period in which such center is in a lead
network established under section 499B(c) of
this Act, receives a grant under section 330;
``(v) a hospital that, during such period,
receives a disproportionate share payment under
section 1886(d)(5)(F) of the Social Security
Act (42 U.S.C. 1395ww(d)(5)(F));
``(vi) a facility owned or operated by the
Indian Health Service;
``(vii) a facility operated by an Indian
Tribe, Tribal organization, or an urban Indian
organization (as such terms are defined in
section 4 of the Indian Health Care Improvement
Act (25 U.S.C. 1603)); or
``(viii) a health care provider that,
during such period, receives a grant under
title XXVI of the Public Health Service Act (42
U.S.C. 300ff et seq.) (commonly known as the
Ryan White HIV/AIDS program).
``(6) Routine point-of-care clinical trial.--The term
`routine point-of-care clinical trial' means a clinical
investigation of a medical product (as defined in section 499B
of this Act) that--
``(A) is integrated into clinical practice,
including routine in-person or virtual visits;
``(B) includes health providers as investigators;
``(C) may be conducted in a primary care setting,
an outpatient care setting, the home of a patient
participating in such investigation, or a similar
location; and
``(D) may follow a streamlined protocol and
procedures focused on essential data collection
generating or incorporating real-world data from an
electronic or other health record.''.
SEC. 105. DATA STANDARDS WITH RESPECT TO DATA SHARING.
(a) In General.--Not later than 18 months after the date of
enactment of this Act, the Administrator of the Centers for Medicare &
Medicaid Services, the Commissioner of Food and Drugs, and the National
Coordinator for Health Information Technology (in this section referred
to as the ``Administrator'') shall establish a list of data standards
for the purpose of facilitating the exchange of patient data for
routine point-of-care clinical trials and contribution to Federal
datasets using established common data models.
(b) Required Contents.--In establishing the list under subsection
(a), the Administrator shall include--
(1) the United States Core Data for Interoperability;
(2) the Fast Healthcare Interoperability Resources standard
maintained by Health Level Seven;
(3) the Clinical Data Acquisition Standards Harmonization
maintained by the Clinical Data Interchange Standards
Consortium; and
(4) the Study Data Tabulation Model maintained by such
Consortium.
(c) Updates to List.--Not less than once every 3 years, the
Administrator shall update the list of data standards established under
subsection (a) to reflect new or successor standards adopted by the
National Coordinator for Health Information Technology pursuant to
section 3001 of the Public Health Service Act (42 U.S.C. 300jj-11).
(d) Technical Specifications and Validation Pathways for Data
Exchange.--Not later than 12 months after the date of enactment of this
Act, the Administrator shall make available to the public on the
website of the Department technical specifications and validation
pathways by which data exchanged, in a manner consistent with the data
standards included on the list established under subsection (a), may be
translated for regulatory submission.
(e) Privacy-Preserving Data Sharing.--The Administrator may
implement data linkage and tokenization capabilities maintained by the
Centers for Medicare & Medicaid Services to support data sharing in
routine point-of-care clinical trials in compliance with--
(1) the Health Insurance Portability and Accountability Act
of 1996 (Public Law 104-191);
(2) section 552a of title 5, United States Code (commonly
referred to as the ``Privacy Act of 1974''); and
(3) part 2 of title 42, Code of Federal Regulations (or any
successor regulation), relating to confidentiality of substance
use disorder patient records.
(f) Implementation Plan.--Not later than 90 days after the date of
enactment of this Act, the Administrator shall make available to the
public on the website of the Department an implementation plan that--
(1) includes milestones for carrying out each activity
under subsections (a) through (e);
(2) designates lead officials at the Centers for Medicare &
Medicaid Services, the Food and Drug Administration, and the
Office of the National Coordinator for Health Information
Technology to carry out such activities;
(3) describes how such activities align with the Cures in
Care Initiative established under section 499B of the Public
Health Service Act, as added by section 101 of this Act; and
(4) describes how technology will be implemented in daily
clinical workflows, such as telehealth, remote monitoring,
eCOA/ePRO, wearables and connected devices, eConsent, EDC,
eSource, and EHR integration, with appropriate expectations for
validation, interoperability, data quality, privacy,
cybersecurity and regulatory use.
(g) Amendment to FDA Guidance.--Not later than 12 months after the
list of data standards is established under paragraph (1), the
Commissioner of Food and Drugs shall update the guidance entitled
``Real-World Data: Assessing Electronic Health Records and Medical
Claims Data To Support Regulatory Decision-Making for Drug and
Biological Products'' (89 Fed. Reg. 60430; issued July 25, 2024) (or
successor guidance) to clarify how a person may use data shared in
compliance with such standards when submitting an application seeking
approval of a medical product, including for--
(1) demonstrating the effectiveness of--
(A) medical products approved under section 506 or
515B of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 356; 21 U.S.C. 360e-3);
(B) a previously approved medical product for a new
indication of use; and
(C) a drug designated as an orphan drug under
section 526 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360bb);
(2) assessing fit-for-purpose validation of digital health
technologies and artificial intelligence tools that capture or
analyze such data for clinical investigations of medical
products; and
(3) assessing how real-world evidence contained in Federal
datasets could be leveraged to support regulatory decision-
making for medical product approval applications.
SEC. 106. CLINICAL TRIAL OVERSIGHT MODERNIZATION.
(a) Single IRB Requirement for Certain Clinical Investigations.--
(1) In general.--Subject to paragraph (2), a sponsor of
multi-institutional or cooperative clinical investigations of
medical products regulated under parts 45 and 56 of title 21,
Code of Federal Regulations (or any successor regulations),
shall designate a single institutional review board with
respect to the review of such investigation.
(2) Exception.--If, in an investigational new drug
application or investigational device exemption application,
the sponsor described in paragraph (1) demonstrates that an
alternative manner of review is necessary and the designation
of only one institutional review board is not appropriate, such
sponsor may, with respect to a clinical investigation--
(A) rely on the review of an institutional review
board local to a site for such clinical investigation;
(B) enter into a joint review arrangement with
institutional review boards; or
(C) make such other arrangement to avoid a
duplication of effort.
(3) Rulemaking.--Not later than 12 months after the date of
enactment of this Act, the Commissioner of Food and Drugs shall
issue such rules as may be necessary to implement this
subsection, including--
(A) amending parts 50 and 56 of title 21, Code of
Federal Regulations (or any successor regulation); and
(B) ensuring implementation of section 3023 of the
21st Century Cures Act (Public Law 114-255).
(4) Definitions.--In this subsection:
(A) Investigational device exemption application.--
The term ``investigational device exemption
application'' means an application submitted pursuant
to part 812 of title 21, Code of Federal Regulations
(or any successor regulation), to request an exemption
for an investigational device (as defined in section
812.3 of such part).
(B) Multi-institutional clinical investigation.--
The term ``multi-institutional clinical investigation''
means a clinical investigation conducted at not less
than two institutions under a single protocol.
(b) IRB Transparency in Decision-Making.--Not later than 1 year
after the date of enactment of this Act, the Secretary of Health and
Human Services, acting through the Assistant Secretary of Health,
Commissioner of Food and Drugs, and the Director of the National
Institutes of Health shall issue such rules as may be necessary to
amend title 21 and title 45, Code of Federal Regulations (and any
successor regulations), to--
(1) expand the public disclosure of Institutional Review
Board (referred to as ``IRB'' in this section) deliberations,
including summaries of key issues in submitted protocols and
summary bases of decisions;
(2) maintain the confidentiality of protected health
information, commercial confidential data, and trade secrets in
such disclosures of IRB deliberations; and
(3) implement such disclosures, to the extent practicable,
through the ClinicalTrials.gov website (or a successor website)
maintained by the National Library of Medicine.
(c) Bioresearch Monitoring Capacity.--The Commissioner of Food and
Drugs shall expand and enhance the bioresearch monitoring capacity of
the Food and Drug Administration through the performance commitments
under section 736B of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 379h-2).
SEC. 107. UPDATES TO PATIENT COSTS AND PAYMENT FOR PARTICIPATION IN
CLINICAL TRIALS.
(a) Enabling Coverage of Patient Costs and Use of Evidence.--
(1) Routine care cost coverage clarification.--
(A) In general.--Not later than 18 months after the
date of enactment of this Act, the Administrator of the
Centers for Medicare & Medicaid Services shall issue
guidance, or update the National Coverage Determination
for Routine Costs in Clinical Trials, to clarify that a
routine point-of-care clinical trial is a qualifying
clinical trial, such that coverage is available under
the Medicare program under title XVIII of the Social
Security Act (42 U.S.C. 1395 et seq.) for routine costs
incurred in connection with such trial, including items
and services furnished in connection with such trial
through digital health tools and through providers
operating in digital-first or remote care modalities.
(B) Alignments with data standards.--The
Administrator shall align the Centers for Medicare &
Medicaid Services quality measurement initiatives with
the data standards established under section 105.
(2) Point-of-care evidence for coverage guidance.--Not
later than 18 months after the date of enactment of this Act,
the Administrator shall issue or update guidance on how
evidence from a routine point-of-care clinical trial may be
applied to--
(A) national coverage determinations (as defined in
section 1869(f)(1)(B) of the Social Security Act (42
U.S.C. 1395ff(f)(1)(B))) and updates thereto; and
(B) coverage of items and services subject to
conditions of evidence development established by the
Secretary under section 1862(a)(1)(A) of the Social
Security Act (42 U.S.C. 1395y(a)(1)(A)), commonly
referred to as coverage with evidence development.
(b) Clinical Trial Participant Payment.--Not later than 1 year
after the date of enactment of this Act, the Secretary, in consultation
with the Commissioner of Food and Drugs and the Director of the Office
of Human Research Protections shall issue such rules as may be
necessary with respect to compensation for participants in a clinical
trial as to ensure compensation is commensurate with the risks and
burdens associated with the research and are not construed as
constituting potential undue influence.
(c) Clinical Trial Site Participant Payment.--Not later than 1 year
after the date of enactment of this Act, the Secretary, in consultation
with the Commissioner of Food and Drugs and the Director of the
National Institutes of Health, shall issue such rules as may be
necessary with respect to fair compensation for site participants in a
clinical trial.
TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT
SEC. 201. MODERNIZED EVIDENCE GENERATION THROUGH NEW APPROACH
METHODOLOGIES.
(a) Guidance for Implementation of New Approach Methodologies.--
(1) In general.--Not later than 2 years after the date of
enactment of this Act, the Secretary, acting through the
Commissioner of Food and Drugs (in this section referred to as
the ``Commissioner''), shall issue guidance and evidence
frameworks, including through amending existing guidance or
frameworks, to facilitate the implementation of new approach
methodologies for the purpose of streamlining and
accelerating--
(A) preclinical pharmacology and toxicology
studies;
(B) submission of investigational new drug
applications; and
(C) early clinical phases of drug development.
(2) Contents.--In issuing guidance under paragraph (1), the
Commissioner shall--
(A) identify leading and novel use cases for in
vitro and in silico technology, including by--
(i) expanding on streamlined nonclinical
programs and acceptable new approach
methodologies;
(ii) describing additional opportunities to
apply such technology to toxicology;
(iii) describing how to validate complex in
vitro and in silico technology as new approach
methodologies; and
(iv) describing the use of human-derived in
vitro and ex vivo systems where a nonclinical
species does not express, or does not
adequately recapitulate binding to, the human
target of a targeted biological product,
including where a species-specific surrogate
molecule would otherwise be required;
(B) implement pathways for the Center for Drug
Evaluation and Research and the Center for Biologics
Evaluation and Research to validate new approach
methodologies, for patients with a rare disease or
other serious and life-threatening conditions,
including the program established under section 507 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
357) and the plausible mechanism framework for rare
diseases implemented by the Food and Drug
Administration;
(C) incorporate--
(i) the information obtained through the
workshops and meetings described in subsection
(b); and
(ii) the policies established under
subsection (c); and
(D) clarify the types and amount of data required
to validate a new approach methodology for a context of
use, and to expand such validated contexts of use.
(b) Public Engagement.--The Commissioner, in consultation with the
Director of the National Institutes of Health, shall hold workshops and
public meetings to engage with sponsors, physicians, researchers,
patients, and other stakeholders to, with respect to the development
and validation of new approach methodologies, including in vitro and in
silico technology--
(1) encourage precompetitive collaboration between
sponsors, researchers, technology developers, and preclinical
research organizations;
(2) identify incentives for sponsor participation,
including protection of intellectual property or such other
proprietary protection, to encourage data sharing from
completed preclinical projects; and
(3) advance collaborative analyses and validations of such
methodologies to reduce development costs and increase the
acceptance of such methodologies for preclinical testing and
regulatory requirements, including by reducing or eliminating
animal testing for new medical products.
(c) Regulatory Innovation.--The Commissioner, in consultation with
the Director of the National Institutes of Health and the Director of
the Advanced Research Projects Agency-Health shall, using the
information obtained through the workshops and meetings described in
subsection (b), establish a policy or platform for accelerated and
precompetitive data sharing for, and analyses and validation of, new
approach methodologies, that includes--
(1) an incentive for sponsor participation, including a
method for regulatory validation of--
(A) digital and artificial intelligence tools;
(B) appropriate data security standards; and
(C) proprietary protection;
(2) a novel or improved validation method for a new
approach methodology based on--
(A) data for such methodology; and
(B) traditional preclinical validation data for the
clinical investigation of a medical product, regardless
of whether such investigation proceeded to human
studies;
(3) a sustainable method of funding, including--
(A) a sponsor applying to a Federal grant or
contract program;
(B) the Secretary establishing a Federal grant or
contract program; or
(C) the Secretary recommending that Congress--
(i) establish a new Federal grant or
contract program for the purposes described in
this section; or
(ii) take other legislative action to
establish such method of funding; and
(4) with respect to regulatory submissions, guidelines for
enhanced collaboration with international regulatory
authorities to advance the use and acceptance of a validated
new approach methodology.
SEC. 202. MODERNIZED PHASE 1 CLINICAL TRIAL OVERSIGHT.
(a) In General.--The Secretary shall establish an expedited
procedure for review and initiation of lower-risk phase 1 trials,
including through--
(1) issuing guidance, including through amending existing
guidance; and
(2) establishing the pilot program under subsection (b).
(b) Pilot Program.--
(1) In general.--The Secretary shall establish a pilot
program for the third-party review of lower-risk phase 1
trials.
(2) Qualified third parties.--
(A) Consideration as qualified third party.--A
third party is qualified to review a lower-risk phase 1
trial under the pilot program established under
paragraph (1) if such third party--
(i) is--
(I) an institutional review board;
or
(II) such other third party, as
determined by the Secretary;
(ii) has technical competency to--
(I) review toxicology data; and
(II) ensure Chemistry,
Manufacturing, and Controls (in this
section referred to as ``CMC'') data is
compliant with good manufacturing
practices in a manner that is
commensurate with any review carried
out by the Commissioner of Foods and
Drugs with respect to investigational
new drug applications; and
(iii) complies with the criteria
established under subparagraph (B).
(B) Qualification criteria.--Using the criteria to
accredit or deny accreditation to persons who request
to perform the duties specified in section 523 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360m)
as a model, the Secretary shall establish criteria by
which a third party may be considered a qualified third
party under subparagraph (A)(iii).
(3) Establishment of pilot program criteria.--In carrying
out the pilot program established under paragraph (1), the
Secretary shall establish criteria for a qualified third party
to review a lower-risk phase 1 trial, including the use of lead
use cases and compliance with best practices for the effective,
efficient, and timely ethical review and safety oversight of
such trial.
(4) Enhanced oversight.--In carrying out the pilot program
established under paragraph (1), the Secretary shall--
(A) collect performance data with respect to such
pilot program;
(B) assess any review carried out under such pilot
program to ensure that the quality of such review is
commensurate with any review carried out by the
Commissioner of Foods and Drugs with respect to
investigational new drug applications; and
(C) audit any qualified third party who conducts
such a review to ensure program integrity.
(5) Extension to higher-risk phase 1 trials.--The Secretary
shall assess--
(A) any information obtained under paragraph (4);
and
(B) the desirability of expanding such pilot
program to include the review of higher-risk phase 1
trials by--
(i) establishing and piloting pre-
certification standards with additional or
enhanced requirements, as appropriate based on
the risk of such trial, including for study
conduct and monitoring, manufacturing, and
adverse event mitigation;
(ii) developing specific guidance and pilot
support for--
(I) a qualified institutional
review board to review such a trial for
a cell or gene therapy, or a gene
editing product;
(II) clear and specific regulatory
discussions for filing investigational
new drug applications;
(III) CMC-readiness by a sponsor or
investigator of such a trial; and
(IV) a dose escalation approach for
such a trial; and
(iii) holding workshops, and publishing
findings from such workshops, to support a
potentially generalizable pre-certification
process for early-stage studies of a cell or
gene therapy, or a gene editing product.
(6) Regulatory harmonization.--The Secretary shall assess
whether subpart A of part 46 of title 45, Code of Federal
Regulations (or any successor regulation), should be amended to
ensure regulatory consistency with any information obtained
under paragraphs (4) and (5).
(c) Requirements With Respect to Establishing Expedited
Procedure.--For purposes of carrying out this section, the Secretary
shall--
(1) establish criteria for classifying a phase 1 trial as a
lower-risk phase 1 trial or a higher-risk phase 1 trial;
(2) assess relevant global regulatory programs with
decentralized and expedited review and approval of phase 1
trials, including the Clinical Trial Notification scheme
established by the Parliament of Australia in the Therapeutic
Goods Act 1989, and any amendments thereto; and
(3) incorporate any findings from such assessment into the
expedited procedure established under subsection (a).
(d) Appropriate Manufacturing Standards.--
(1) Proposed rule.--Not later than 1 year after the date of
enactment of this Act, the Secretary shall issue a proposed
rule to revise such sections in title 21, Code of Federal
Regulations (or any successor regulations), relating to current
good manufacturing practices for drugs, as may be necessary to
ensure that, for an unapproved new drug or investigational drug
intended for use in a lower-risk phase 1 trial, the burden of
complying with CMC does not unnecessarily impede the initiation
of such trial.
(2) Considerations.--In determining whether to revise a
regulation under paragraph (1), the Secretary shall consider--
(A) the criteria established under subsection
(c)(1);
(B) the risk associated with lower-risk phase 1
trials;
(C) the limited number of patients typically
enrolled in phase 1 trials;
(D) the use of small-batch, non-continuous
manufacturing processes;
(E) the clinical setting of lower-risk phase 1
trials, including--
(i) academic medical centers; or
(ii) in the case of routine point-of-care
clinical trials, primary care and outpatient
care settings; and
(F) the extent to which guidance for
investigational drugs intended for use in lower-risk
phase 1 trials can be included in regulation to provide
greater regulatory certainty.
(3) Final rule.--Not later than 1 year after the date on
which the comment period ends for the proposed rule issued
under paragraph (1), the Secretary shall--
(A) incorporate any information obtained under
subsection (b)(4); and
(B) finalize such rule.
(e) Definitions.--In this section:
(1) Higher-risk phase 1 trial.--The term ``higher-risk
phase 1 trial'' means a phase 1 trial--
(A) of an investigational drug that is intended to
result in, or is capable of resulting in, modification
of the genome of a human cell, including by
integration, insertion, deletion, or base or prime
editing;
(B) of an investigational drug that is replication-
competent or capable of horizontal transfer;
(C) of an investigational drug the biological
activity of which cannot be discontinued by cessation
of dosing;
(D) of an investigational drug intended to produce
sustained engagement of immune effector cells with an
antigen expressed on essential non-malignant human
tissue;
(E) of an investigational drug for which any prior
clinical investigation has been placed on clinical hold
pursuant to section 312.42 of title 21, Code of Federal
Regulations (or any successor regulation); or
(F) that is more likely to expose human subjects to
an unreasonable and significant risk of illness or
injury.
(2) Lower-risk phase 1 trial.--The term ``lower-risk phase
1 trial'' means a phase 1 trial--
(A) that presents a minimal potential for harm to a
patient;
(B) that is an exploratory or phase 0 study of
subtherapeutic or non-toxic doses with no therapeutic
intent; or
(C) that is a study initiated by an investigator.
(3) Phase 1 trial.--The term ``phase 1 trial'' means phase
1 of a clinical investigation of a previously untested drug, as
described in section 312.21 of title 21, Code of Federal
Regulations (or any successor regulation).
SEC. 203. GLOBAL REGULATORY ALIGNMENT TO MODERNIZE CLINICAL
DEVELOPMENT.
(a) In General.--Section 803 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 383) is amended--
(1) in subsection (b)--
(A) in paragraph (1), by striking ``, and'' and
inserting a semicolon;
(B) by redesignating paragraph (2) as paragraph
(4); and
(C) by adding after paragraph (1) the following:
``(2) the standard, entitled `Good Clinical Practice',
maintained by the International Council for Harmonisation;'';
and
(2) by adding at the end the following:
``(d)(1) The Secretary shall expand and coordinate efforts,
including through enhanced international collaboration, to ensure
compliance with the standard, entitled `Good Clinical Practice',
maintained by the International Council for Harmonisation for clinical
trials conducted outside the United States.
``(2) The Secretary shall, in consultation with relevant nations
and the International Council for Harmonisation, foster global
regulatory alignment to modernize clinical early-stage medical product
development, integrate real-world data and digital health information
into clinical investigations, and ensure regulatory acceptance of
investigations conducted by clinical trial networks embedded in routine
practice.''.
(b) Enhancing Data Integrity and Oversight of Clinical Trials at
Sites of Concern.--Section 704 of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 374) is amended by adding at the end the following:
``(i)(1) With respect to an owner, operator, or agent in charge of
an establishment carrying out a clinical investigation intended to
support an application under section 505 of this Act or section 351 of
the Public Health Service Act (42 U.S.C. 262), the Secretary shall, as
part of the inspection of such establishment under this section--
``(A) require such owner, operator, or agent to pre-certify
that such clinical investigation complies with the standard,
entitled `Good Clinical Practice', maintained by the
International Council for Harmonisation; and
``(B) verify, on-site or remotely, that, prior to the
acceptance of data from any clinical trial site, contract
research organization, or data management vendor that meets the
criteria of a biotechnology company of concern (as defined in
section 851(f)(2) of the National Defense Authorization Act for
Fiscal Year 2026 (Public Law 119-60)), such clinical
investigation complies with--
``(i) such standard; and
``(ii) data security protocols.
``(2) The Secretary may require an owner, operator, or agent
described in paragraph (1) to pay a fee to cover any cost related to
the activities described in such paragraph.''.
(c) Strengthening Foreign Early-Phase Data Verification.--
(1) Documentation requirement.--The Secretary may, with
respect to any patient-level data from a phase 1 or phase 2
clinical investigation conducted outside of the United States,
require a sponsor or investigator to submit documentation of
such patient-level data for purposes of ensuring the integrity
of such investigation, such as--
(A) source data and audit trails for each primary
or secondary endpoint tested in such investigation;
(B) records of informed consent, translated into
English;
(C) the chain of custody for each biological sample
and test article used in such investigation; and
(D) other documentation as deemed necessary by the
Secretary.
(2) Refusal of data.--The Secretary may refuse to accept
such patient-level data if a sponsor or investigator does not
comply with the requirement to provide documentation pursuant
to paragraph (1).
(d) Guidance on Data Integrity and Inspection Access.--Not later
than 18 months after the date of enactment of this Act, the Secretary
shall revise the guidance issued by the Food and Drug Administration,
entitled ``Guidance for Industry: Circumstances that Constitute
Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection'',
(issued June 2024) to provide clarification on any action the Secretary
will take if a person does not comply with any requirement established
by the Secretary under section 704(i) of the Federal Food, Drug, and
Cosmetic Act, as added by subsection (b) of this section.
SEC. 204. MINIMUM UNITED STATES REPRESENTATION IN CLINICAL TRIALS.
(a) In General.--The Secretary of Health and Human Services shall
require that each pivotal study submitted in support of an application
under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42
U.S.C. 262(a)) meet the requirements of subsection (b).
(b) U.S. Participation.--A pivotal study contained in an
application under section 505(b) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health
Service Act (42 U.S.C. 262(a))--
(1) may not be based solely on foreign clinical data;
(2) shall include patients enrolled at clinical
investigation sites in the United States, including as part of
a multi-national clinical trial to support such application;
(3) shall align with international harmonization efforts,
including the guidance issued by the International Council for
Harmonisation, entitled ``General Principles for Planning and
Design of Multi-Regional Clinical Trials'' (E17; adopted
November 16, 2017); and
(4) shall include any other evaluation metrics as
determined by the Secretary, including if--
(A) the drug or biological product that is the
subject of the application described in this Act is
intended to treat a rare disease or condition;
(B) the Secretary determines that foreign clinical
data--
(i) is derived from a clinical
investigation conducted in accordance with good
clinical practice;
(ii) is applicable to the United States
population and United States medical practice;
and
(iii) is validated through an on-site
inspection of the relevant trial site or other
appropriate means, as determined by the
Secretary;
(C) clinical investigation sites in the United
States are unavailable;
(D) establishing a clinical investigation site in
the United States is otherwise impracticable; or
(E) a waiver is necessary to protect public health
during a public health emergency.
SEC. 205. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.
The Federal Food, Drug, and Cosmetic Act is amended by adding after
section 1014 (21 U.S.C. 360ff-1) the following:
``SEC. 1014A. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.
``(a) Food and Drug Administration Rare Disease Innovation Hub.--
The Secretary shall establish the Food and Drug Administration Rare
Disease Innovation Hub (in this section referred to as the `Hub') as an
Intercenter Institute described in section 1014 to--
``(1) advance regulatory science for a rare disease or
condition;
``(2) provide technical assistance to review teams
assessing rare disease medical products to ensure reviewer
consistency and documentation of agreements upon acceptable
trial designs;
``(3) promote innovation of rare disease medical products;
``(4) leverage lead networks (established in title I of the
Faster Clinical Trials Act), interoperable technology and data
infrastructure, and public-private collaboration mechanisms to
advance natural history studies, distributed and platform
clinical trials, biomarker and clinical outcome assessment
development, and fit-for-purpose evidence generated from real-
world data generation for rare diseases;
``(5) enhance coordination, alignment, and collaboration
between the heads of the Directors listed in subsection (b)(1)
and other Intercenter Institutes established under section 1014
with respect to the development and regulation of rare disease
medical products;
``(6) foster and support dialogue and public-private
partnerships with patients who have, and providers that treat,
a rare disease or condition to ensure such development is
patient-focused;
``(7) allow sponsors to consult with the Hub regarding
questions, concerns, or deliberations throughout the review
process; and
``(8) function as a point of escalation for sponsors of
rare disease medical products to request re-review or
consultation regarding review decisions.
``(b) Activities.--In addition to the activities of an Intercenter
Institute described in section 1014, the Hub shall--
``(1) facilitate collaboration, information sharing,
regulatory consistency, and cross-disciplinary training and
product reviews with--
``(A) the Office of Orphan Products Development;
``(B) the Center for Drug Evaluation and Research;
``(C) the Center for Biologics Evaluation and
Research;
``(D) the Center for Devices and Radiological
Health; and
``(E) the Oncology Center of Excellence; and
``(2) award grants, cooperative agreements, or contracts,
or enter into memoranda of understanding, to--
``(A) support natural history studies, the use of
novel clinical trial designs, and the application of
the plausible mechanism evidentiary framework;
``(B) accelerate the development and validation of
early and novel biomarkers and endpoints for rare
diseases or conditions, pursuant to section 507 of this
Act and section 3208 of the Food and Drug Omnibus
Reform Act (Public Law 117-328);
``(C) ensure targeted technical assistance is
provided for--
``(i) investigator-initiated clinical
trials for medical products intended to treat
rare diseases or conditions; and
``(ii) patient-sponsored development
programs for such medical products;
``(D) hold meetings and workshops to engage
directly with--
``(i) rare disease patient organizations
and families of patients with rare diseases or
conditions;
``(ii) developers of rare disease medical
products; and
``(iii) researchers and specialty medical
societies; and
``(E) assist in addressing scientific, clinical,
and policy issues related to the development and
regulation of such products.
``(c) Public-Private Partnerships and Consortia.--The Hub shall
foster public-private partnerships or consortia to support the
activities required under this section, including initiatives to--
``(1) de-risk and facilitate access to manufacturing
capacity, including at Federal laboratories and facilities,
for--
``(A) investigator-initiated clinical trials for
rare disease medical products; and
``(B) patient-sponsored development programs for
such medical products; and
``(2) support clinical trials for, and development of, such
a medical product through a national network of clinical
centers of excellence for rare diseases or conditions.
``(d) Report.--Not later than 9 months after the date of enactment
of this subsection, the Secretary shall submit to the Committee on
Energy and Commerce of the House of Representatives and the Committee
on Health, Education, Labor, and Pensions of the Senate, and make
available to the public, a report containing recommendations on the
development and regulation of a medical product intended to treat a
rare disease or condition, including--
``(1) whether to selectively restore the establishment
license application under section 351 of the Public Health
Service Act (42 U.S.C. 262) to facilitate the manufacture of
rare disease medical products by nontraditional sponsors; and
``(2) whether to enhance regulatory flexibility and
manufacturing capacity for nontraditional sponsors, such as
academic laboratories or patient organizations, of--
``(A) an investigator-initiated clinical trial for
a rare disease medical product;
``(B) a patient-sponsored development program for
such a medical product; and
``(C) research and development for medical products
intended to treat or diagnose very rare and n-of-1
diseases or conditions.
``(e) Funding.--
``(1) In general.--To carry out this section, the Secretary
shall transfer to the Hub for each of fiscal years 2027 through
2031--
``(A) $5,000,000 from the amounts made available in
the FDA Innovation Account under section 1002(b)(2)(A)
of the 21st Century Cures Act (Public Law 114-255);
``(B) $10,000,000 from the amounts made available
under section 481A of the Public Health Service Act (42
U.S.C. 287a-2) for clinical research into, training in,
and demonstration of diagnostic, prevention, control,
and treatment methods for rare diseases; and
``(C) $15,000,000 from the amounts made available
to carry out section 499A(f) of such Act (42 U.S.C.
290c(f)), related to cooperation of the Advanced
Research Projects Agency-Health with the Food and Drug
Administration to facilitate the development of medical
products and projects that are the highest priorities
to the Advanced Research Projects Agency-Health.
``(2) Budget clarification.--Any budget request of the
President shall specify an amount for carrying out this
section.
``(f) Definitions.--In this section:
``(1) Medical product.--The term `medical product' means--
``(A) a drug or device, as defined in section 201
of this Act; or
``(B) a biological product, as defined in section
351 of the Public Health Service Act (42 U.S.C. 262).
``(2) Rare disease or condition.--The term `rare disease or
condition' has the meaning given such term in section 526.''.
TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT
INNOVATION
SEC. 301. RESOLVING CLINICAL HOLDS AND IMPROVING CLINICAL TRIAL
EFFICIENCY.
(a) In General.--For purposes of improving the efficiency and
integrity of clinical investigations, the Secretary shall address any
root cause of a clinical hold imposed under section 312.42 of title 21,
Code of Federal Regulations (or any successor regulation), or the
disapproval or withdrawal of approval of an investigational device
exemption under section 812.30 of such title (or any successor
regulation), including--
(1) identifying common sources of noncompliance with such
regulations and common causes of clinical holds and development
delays, with a focus on first-time sponsors of a clinical trial
and investigator-initiated clinical trials, IRBs, CROs and
other experienced implementation and technology partners,
research sites;
(2) developing and disseminating best practices for--
(A) compliance with good clinical practices;
(B) efficient development, filing, and review of
investigational new drug applications and
investigational device exemptions; and
(C) increasing the frequency and documentation of
in-person meetings for sponsors of investigational new
drug applications and investigational device exemptions
in lieu of written responses to provide specific,
authoritative, and consistent guidance with a focus on
action items and enhancements;
(3) early and additional sponsor engagement consistent
with, and additive to, the performance commitments under
section 736B of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 379h-2) to--
(A) secure rapid alignment on a trial design in
support of a complete application for a proposed
indication of use; and
(B) create additional opportunities for informal,
rapid feedback to such a sponsor, including science-
focused drug development meetings;
(4) increasing the use of external advisory committees;
(5) early and consistent integration of staff with
requisite expertise in rare diseases or conditions, as
appropriate, in review teams for the review of investigational
and premarket new drug applications;
(6) clarifying what information qualifies to be redacted
when disclosing complete response letters to the public;
(7) revising procedures and guidance for--
(A) clarifying what information must be redacted
when publicly disclosing complete response letters and
other investigational and premarket new drug
application materials to the public;
(B) developing and publicly disclosing novel
redaction methods and tools, including automation or
artificial intelligence;
(C) the timely public disclosure of complete
response letters and other investigational and
premarket new drug application materials; and
(D) the establishment of pilot programs to
facilitate timely public access to such letters and
such application materials; and
(8) creating a designated Food and Drug Administration
contact for process and regulatory-navigation questions for
emerging biotechnology companies.
(b) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $500,000,000 for each of the
fiscal years 2027 through 2031, to remain available until expended.
SEC. 302. MUTUAL RECOGNITION OF GMP STANDARDS.
(a) Recognition of Foreign Government Inspections.--Section 809 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e) is amended--
(1) in subsection (a)--
(A) in paragraph (2), by striking ``and'' at the
end;
(B) in paragraph (3), by striking the period at the
end and inserting ``; and''; and
(C) by inserting after paragraph (3) the following:
``(4) shall implement a procedure for exchanging inspection
reports with a foreign government or an agency of a foreign
government that the Secretary has entered into an arrangement
or agreement with under this section to avoid duplicating an
inspection in which a foreign establishment registered under
section 510 was found to be in compliance with good
manufacturing practice regulations promulgated under section
501.'';
(2) by redesignating subsection (c) as subsection (d);
(3) by inserting after subsection (b) the following:
``(c) Risk-Based Prioritization Plan.--For purposes of increasing
the rate of inspections, the Secretary shall implement a plan for the
use of risk-based prioritization for inspections of establishments
registered under section 510, which shall include consideration of--
``(1) the history of such an establishment with respect to
complying with good manufacturing practice regulations
promulgated under section 520(f);
``(2) the inherent risk of the drug or device manufactured,
prepared, propagated, compounded, or processed (as defined in
section 510) at such establishment; and
``(3) the availability of recent inspection reports from a
foreign government or an agency of a foreign government that
the Secretary has entered into an arrangement or agreement with
under this section.''; and
(4) in paragraph (2) of subsection (d), as redesignated by
paragraph (2) of this section--
(A) by striking ``Beginning not later'' and
inserting the following:
``(A) In general.--Beginning not later''; and
(B) by adding at the end the following:
``(B) Reporting on mutual recognition.--The report
under subparagraph (A) shall include, with respect to
the period covered by the report an update on the
status of any agreement the Secretary enters into with
a foreign country under section 803 related to
encouraging the mutual recognition of good
manufacturing practice regulations promulgated under
section 520(f) with respect to inspections.''.
(b) Expansion of Mutual Recognition Agreements to Bioresearch
Monitoring.--Section 803(b) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 383(b)) is amended by inserting after paragraph (2), as
inserted by section 203(a)(1)(C), the following:
``(3) the bioresearch monitoring program implemented by the
Food and Drug Administration through compliance programs shall
identify ways to--
``(A) allow such countries to rely on any
inspection conducted by the Food and Drug
Administration related to an establishment performing
clinical research;
``(B) reduce the regulatory burden on such an
establishment in the United States; and
``(C) provide the Secretary with maximum
flexibility to focus resources related to inspections
and compliance on establishments that pose the greatest
risk to data integrity or safety.''.
SEC. 303. PATHWAY FOR COMPETITIVE GENERIC THERAPIES.
(a) Review.--The Secretary shall review and provide recommendations
to improve the pathway for competitive generic therapies established
pursuant to section 506H of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 356h) no later than 12 months after the date of the
enactment of this Act.
(b) Improvement.--Following the review under paragraph (1), the
Secretary shall--
(1) report the review, its findings, and any
recommendations to committees of jurisdiction within 12 months
of the date of the enactment of this Act; and
(2) not later than 6 months after transmitting the review
to Congress, begin implementing the recommendations.
(c) Collaboration.--In carrying out this section, the Secretary
shall incorporate the perspectives of health care stakeholders.
SEC. 304. BIOSIMILAR BIOLOGICAL PRODUCTS.
(a) In General.--Section 351(k) of the Public Health Service Act
(42 U.S.C. 262(k)) is amended--
(1) in the subsection heading, by striking ``or
Interchangeable'';
(2) in paragraph (2)--
(A) by striking subparagraph (B);
(B) by redesignating clauses (ii) and (iii) of
subparagraph (A) as subparagraphs (B) and (C),
respectively, and adjusting the margins accordingly;
(C) in subparagraph (A)--
(i) in clause (i), by redesignating
subclauses (I) through (V) as clauses (i)
through (v), respectively, and adjusting the
margins accordingly;
(ii) in clause (i), as so redesignated by
clause (i) of this subparagraph, by
redesignating items (aa) through (cc) as
subclauses (I) through (III), respectively, and
adjusting the margins accordingly;
(iii) in subclause (II) of clause (i), as
so redesignated by clause (ii) of this
subparagraph, by striking ``item (aa) or (cc)''
and inserting ``subclause (I) or (III)''; and
(iv) by striking ``(A) in general'' and all
that follows through ``An application submitted
under this subsection shall include
information'' and inserting the following:
``(A) In general.--An application submitted under
this subsection shall include information'';
(D) in subparagraph (B), as so redesignated by
subparagraph (B) of this paragraph, by striking
``clause (i)(I)'' and inserting ``subparagraph
(A)(i)''; and
(E) in subparagraph (C), as so redesignated by
subparagraph (B) of this paragraph, by redesignating
subclauses (I) through (III) as clauses (i) through
(iii), respectively, and adjusting the margins
accordingly;
(3) by amending subparagraph (A) of paragraph (3) to read
as follows:
``(A) the Secretary determines that the information
submitted in the application (or the supplement) is
sufficient to show that the biological product is
biosimilar to the reference product; and'';
(4) by amending paragraph (4) to read as follows:
``(4) Interchangeability.--
``(A) In general.--A biological product licensed
under this subsection shall be deemed to be
interchangeable with the reference product, subject to
subparagraph (B).
``(B) Timing of deemed interchangeability.--
``(i) Licensure on or after transition
date.--A biological product licensed under this
subsection on or after the transition date
described in subparagraph (C) (in this clause
referred to as the `applicable biological
product') shall be deemed to be interchangeable
with the reference product upon such licensure,
unless the applicable biological product relied
on the same reference product as another
biological product for which--
``(I) licensure under this
subsection was in effect on the day
before the date of enactment of the
Faster Clinical Trials Act; and
``(II) a first interchangeable
exclusivity period under paragraph (6)
(as in effect on the day before the
date of enactment of such Act) is in
effect on the date of licensure of the
applicable biological product,
in which case the applicable biological product
shall be deemed interchangeable with the
reference product under this paragraph on the
date on which the exclusivity period described
in subclause (II) ends.
``(ii) Licensure prior to transition
date.--A biological product licensed under this
subsection prior to the transition date
described in subparagraph (C) (referred to in
this clause as the `applicable biological
product') shall be deemed to be interchangeable
with the reference product on such transition
date, unless the applicable biological product
relied on the same reference product as another
biological product for which--
``(I) licensure under this
subsection was in effect on the day
before the date of enactment of the
Faster Clinical Trials Act; and
``(II) a first interchangeable
exclusivity period under paragraph (6)
(as in effect on the day before the
date of enactment of such Act) is in
effect on the transition date,
in which case the applicable biological product
shall be deemed interchangeable with the
reference product under this paragraph on the
date on which the exclusivity period described
in subclause (II) ends.
``(C) Transition date.--The transition date
described in this subparagraph is the date that is 60
days after the date of enactment of the Faster Clinical
Trials Act.'';
(5) by amending paragraph (6) to read as follows:
``(6) Transition with respect to preserving first
interchangeable exclusivity with respect to certain biological
products.--With respect to a biological product licensed under
this subsection before the date of enactment of the Faster
Clinical Trials Act, for which there was an unexpired period of
first interchangeable exclusivity under this subsection (as
then in effect), such unexpired exclusivity period shall remain
in effect for the duration of such period.''; and
(6) in paragraph (8)(D)--
(A) in clause (i), by striking ``class; and'' and
inserting ``class.'';
(B) by striking clause (ii); and
(C) by striking ``description of--'' and all that
follows through ``criteria that the Secretary'' and
inserting ``description of the criteria that the
Secretary''.
(b) Conforming Amendments.--
(1) Section 351(i)(3) of the Public Health Service Act (42
U.S.C. 262(i)(3)) is amended by striking ``that is shown to
meet the standards described in subsection (k)(4)'' and
inserting ``licensed under subsection (k)''.
(2) Section 352A of the Public Health Service Act (42
U.S.C. 263-1) is amended by striking ``and interchangeable
biosimilar biological products'' each place such term appears.
(3) Section 744G(14) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 379j-51(14)) is amended by striking ``,
including a supplement requesting that the Secretary determine
that the biosimilar biological product meets the standards for
interchangeability described in section 351(k)(4) of the Public
Health Service Act''.
(4) Section 505B(l) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 355c(l)) is amended to read as follows:
``(l) Biosimilar Biological Products.--A biological product for
which an application is submitted under section 351(k) of the Public
Health Service Act shall be considered to have a new active ingredient
for purposes of this section only if--
``(1) the application seeks licensure for a claimed
indication--
``(A) that has been approved for a relevant
pediatric population; or
``(B) for which there is a deferral of a relevant
pediatric assessment under subsection (a)(4) of this
section for the reference product applicant; and
``(2) a pediatric assessment under this section would not
involve the development of a biological product with a
strength, dosage form, route of administration, and condition
of use for which there would not be a reference product.''.
(c) Guidance.--The Secretary shall--
(1) not later than 18 months after the date of enactment of
this Act, update existing draft and final guidance to reflect
the amendments made by this section, including by revising or
revoking the guidance entitled ``Considerations in
Demonstrating Interchangeability With a Reference Product''
(May 2019) and ``Considerations in Demonstrating
Interchangeability With a Reference Product: Update'' (June
2024);
(2) not later than 18 months after the date of enactment of
this Act, issue or revise guidance on review and approval of
biosimilar biological products under section 351(k) of the
Public Health Service Act (42 U.S.C. 262(k)) relating to the
data and information that an applicant is required to submit to
support a determination that a biosimilar biological product
that is the subject of an application under such section is
biosimilar to the reference product (as defined in section
351(i) of such Act (42 U.S.C. 262(i))); and
(3) not later than 18 months after the comment period
closes on the guidance under paragraphs (1) and (2), issue
revised draft or final versions of such guidance.
(d) Rule of Construction.--The amendments made by this section
shall not be construed--
(1) to alter the standard or the information required for
licensure of a biological product as biosimilar to a reference
product pursuant to section 351(k) of the Public Health Service
Act (42 U.S.C. 262(k)); or
(2) to limit the information that may be required by the
Secretary to support the licensure of a biological product as
biosimilar to a reference product pursuant to such section.
SEC. 305. CERTIFICATION OF PATENT INFORMATION IN CERTAIN APPLICATIONS
FOR BIOLOGICAL PRODUCTS.
Section 351 of the Public Health Service Act (42 U.S.C. 262) is
amended by adding at the end the following:
``(o) Certification of Patent Information in Certain
Applications.--
``(1) In general.--An application submitted under this
section for a biological product that includes a full report of
a covered investigation shall also include--
``(A) a certification, in the opinion of the
applicant and to the best of their knowledge, with
respect to each covered patent--
``(i) that such patent information has not
been filed;
``(ii) that such patent has expired;
``(iii) of the date on which such patent
will expire; or
``(iv) that such patent is invalid or will
not be infringed by the manufacture, use, or
sale of such product for which the application
is submitted; and
``(B) if information was filed under subsection (l)
for a method of use patent which does not claim a use
for which the applicant is seeking approval under this
section, a statement that the method of use patent does
not claim such a use.
``(2) Definitions.--In this subsection:
``(A) Covered investigation.--The term `covered
investigation' means, with respect to a biological
product for which an applicant submitted an application
under this section, an investigation of such product
that--
``(i) was conducted to demonstrate whether
such product is safe for use and is effective
in use;
``(ii) was not conducted by or for the
applicant and for which the applicant has not
obtained a right of reference or use from the
person by or for whom the investigation was
conducted; and
``(iii) is relied upon by the applicant
seeking approval of such application.
``(B) Covered patent.--The term `covered patent'
means a patent--
``(i) which claims--
``(I) the biological product for
which a covered investigation was
conducted; or
``(II) a use for such product for
which an applicant is seeking approval
of an application under this section;
and
``(ii) for which information is required to
be filed under subsection (l).''.
SEC. 306. GAO REPORT.
Not later than 3 years after the date of enactment of this Act, the
Comptroller General of the United States shall submit to Congress a
report evaluating--
(1) any progress in implementing section 301 during the
period covered by the report;
(2) dissemination by the Food and Drug Administration of
resources related to developing a drug;
(3) implementation by the Secretary of pilot programs using
fees made available pursuant to subchapter C of chapter VII of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379f et
seq.), such as the Split Real Time Application Review pilot
program, the Model-Informed Drug Development Paired Meeting
Program, and the Chemistry, Manufacturing, and Controls
Development and Readiness Pilot Program;
(4) implementation by the Secretary of each program
established by this Act or an amendment made by this Act to
improve clinical trial efficiency and ensure regulatory
consistency; and
(5) whether implementing each such program has had a
beneficial impact on the development of a medical product for a
rare disease or condition, including a rare cancer.
SEC. 307. DEFINITIONS.
In this Act:
(1) Clinical investigation.--The term ``clinical
investigation'' has the meaning given such term in section 50.3
of title 21, Code of Federal Regulations (or any successor
regulation).
(2) Department.--The term ``Department'' means the
Department of Health and Human Services.
(3) Good clinical practice.--The term ``good clinical
practice'' means the standard, entitled ``Good Clinical
Practice'', maintained by the International Council for
Harmonisation and implemented by the Secretary.
(4) Institutional review board.--The term ``institutional
review board'' has the meaning given such term in section
56.102 of title 21, Code of Federal Regulations (or any
successor regulation).
(5) Investigational new drug application.--The term
``investigational new drug application'' means an application
submitted pursuant to part 312 of title 21, Code of Federal
Regulations (or any successor regulation), for an
investigational new drug (as defined in section 312.3 of such
part).
(6) Medical product.--The term ``medical product'' means--
(A) a drug or device, as defined in section 201 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
321); or
(B) a biological product, as defined in section 351
of the Public Health Service Act (42 U.S.C. 262).
(7) Rare disease or condition.--The term ``rare disease or
condition'' has the meaning given such term in section 526(a)
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
360bb(a)).
(8) Routine point-of-care clinical trial.--The term
``routine point-of-care clinical trial'' means a clinical
investigation of a medical product that--
(A) is integrated into clinical practice, including
routine in-person, or virtual, visits;
(B) includes health providers as investigators;
(C) may be conducted in a primary care setting, an
outpatient care setting, the home of a patient
participating in such investigation, or a similar
location; and
(D) may follow a streamlined protocol and
procedures focused on essential data collection
generating or incorporating real-world data from an
electronic or other health record.
(9) Secretary.--The term ``Secretary'' means the Secretary
of Health and Human Services.
TITLE IV--PRECISION ONCOLOGY MODERNIZATION
SEC. 401. FINDINGS AND PURPOSE.
(a) Findings.--Congress finds the following:
(1) Advances in molecular oncology have enabled the
identification of specific genetic alterations that drive
certain cancers, enabling the development of targeted therapies
with high efficacy in defined patient populations.
(2) Approved oncology drug labels frequently reflect
clinical trial populations that predate the routine use of
genomic profiling and may not adequately reflect current
scientific understanding of patient subpopulations for whom a
given therapy is inappropriate.
(3) Outdated labeling can contribute to suboptimal
treatment sequencing, unnecessary toxicity, and foregone
opportunity for patients to receive a more precisely and
effective targeted treatment option.
(4) The Food and Drug Administration's Project Renewal
initiative, established to modernize drug product labeling to
reflect contemporary scientific and clinical knowledge,
provides a foundation that can be expanded to systematically
address genomic exclusions in oncology drug labels.
(5) A formal, science-driven process for incorporating
genomic exclusion criteria into oncology labeling would promote
precision medicine, improve patient outcomes, and advance the
efficient use of health care resources.
(b) Purpose.--To establish a process for reviewing and updating the
labeling of approved oncology drugs to reflect genetically defined
patient subpopulations.
SEC. 402. ONCOLOGY CENTER OF EXCELLENCE.
(a) In General.--The Secretary shall establish the Food and Drug
Administration Oncology Center of Excellence as an Intercenter
Institute described in section 1014 to promote development and
facilitate the review of medical products intended to diagnose and
treat oncologic and hematologic malignancies, including--
(1) cancers in infants, children, and adolescents; and
(2) rare cancers.
(b) Activities.--In addition to the activities of an Intercenter
Institute described in section 1014, the Oncology Center of Excellence
shall--
(1) sponsor or conduct projects to advance the development
and regulation of medical products for patients with cancer,
including--
(A) Project Orbis a collaborative framework to
facilitate the concurrent submission and collaborative
regulatory review of oncology products among
international regulatory authorities to expedite global
patient access to safe and effective cancer treatments;
(B) Project Optimus a program to reform dose
optimization and selection for oncologic therapies by
encouraging multi-dose characterization early in
clinical development;
(C) Real-Time Oncology Review (RTOR) a voluntary
pilot program for the early submission of data modules
prior to the formal filing of a complete oncology
marketing application to streamline regulatory review;
(D) Project Confirm a public framework for the
monitoring of confirmatory clinical trials required
under the accelerated approval pathway for oncology
indications to track the confirmation of clinical
benefit;
(E) Project Pragmatica a program to integrate
pragmatic clinical trial designs into the evaluation of
approved oncology medical products, utilizing
streamlined eligibility criteria and real-world
clinical practice settings to reduce operational
burdens on patients and investigators; and
(F) Project Renewal a program to assess information
that may inform updates to the labeling of oncology
drugs to incorporate genomic exclusion criteria;
(2) assist in addressing scientific, clinical, and policy
issues related to the development and regulation of oncology
and hematology products;
(3) award grants, cooperative agreements, or contracts, or
enter into memoranda of understanding, and foster public-
private partnerships or consortia to support the activities
required under this section; and
(4) hold meetings and workshops to engage directly with--
(A) cancer patient organizations and families of
patients with cancer;
(B) developers of oncology and hematology products;
and
(C) researchers and specialty medical societies.
(c) Funding.--
(1) In general.--To carry out this section, the Secretary
shall transfer to the Oncology Center of Excellence for each of
fiscal years 2027 through 2031--
(A) such sums as necessary from the amounts made
available in the FDA Innovation Account under section
1002(b)(2)(A) of the 21st Century Cures Act (Public Law
114-255);
(B) such sums as necessary from amounts made
available pursuant to interagency transfers and
agreements, including with the National Cancer
Institute, as authorized under 31 U.S.C. 1535; and
(C) such sums as necessary from the amounts made
available to carry out section 499A(f) of such Act (42
U.S.C. 290c(f)), related to cooperation of the Advanced
Research Projects Agency-Health with the Food and Drug
Administration to facilitate the development of medical
products and projects that are the highest priorities
to the Advanced Research Projects Agency-Health.
(2) Budget clarification.--Any budget request of the
President shall specify an amount for carrying out this
section.
SEC. 403. LABELING REVISIONS FOR GENOMIC EXCLUSIONS IN ONCOLOGY DRUGS.
(a) In General.--Not later than 12 months after the date of
enactment of this Act, the Secretary shall establish, acting through
the Food and Drug Administration Oncology Center of Excellence
(hereinafter referred to as the ``Center''), a program to assess
information that may inform updates to the labeling of approved
oncology drugs to incorporate genomic exclusion criteria (hereinafter
referred to as the ``Program'').
(b) Duties.--In carrying out the Program, the Center shall--
(1) identify oncology drugs approved under 505(b) or 505(j)
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)
or (j)), or licensed under section 351 of the Public Health
Service Act (42 U.S.C. 262) for which--
(A) there is new scientific evidence available
pertaining to one or more actionable genetic
alterations that is not reflected in the approved
labeling of such drugs; and
(B) the updating of such approved labeling would
benefit the public health; and
(2) establish a process to--
(A) identify such drugs, including--
(i) the procedures authorized under section
503D(b) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 353d(b)), to receive clinical
evidence on the impact of actionable genetic
alterations on patient outcomes; and
(ii) engagement through meetings and
workshops authorized under section 3(b)(4)
with--
(I) holders of approved oncology
drug applications and other drug
sponsors;
(II) the Food and Drug
Administation Rare Disease Innovation
Hub;
(III) the National Cancer
Institute; and
(IV) patient advocacy
organizations, oncology professional
societies, diagnostic test developers,
and other relevant stakeholders;
(B) develop standardized language for genomic
exclusion criteria to support clear statements
regarding the additional, modified, or supplemental
information for amended oncology drug labeling;
(C) encourage holders of approved oncology drug
applications to submit voluntary labeling supplements
to incorporate genomic exclusion criteria, including as
supplemental applications described in sections 314.70
and 601.12 of title 21, Code of Federal Regulations (or
any successor regulations); and
(D) initiate labeling changes to incorporate
genomic exclusion criteria, including under section
505(o) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(o)) and in a manner consistent with the
requirements of section 503D(f)(2) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 353D(f)(2)).
(c) Selection of Oncology Drugs.--The Center shall identify
oncology drugs under this section--
(1) based on factors including--
(A) the strength and consistency of clinical
evidence supporting the impact of the action genetic
alteration on patient outcomes;
(B) the availability of one or more approved
targeted oncology therapies addressing the relevant
actionable genetic alteration or oncogenic driver;
(C) the prevalence of the relevant genetic
alteration or oncogenic driver in the indicated patient
population; and
(D) the potential clinical impact of failing to
identify and exclude patients with the relevant
alteration;
(2) on the basis of the available scientific evidence for
incorporating genomic exclusion criteria into oncology drug
labeling that meets the standards under section 505 for adding
or modifying information to the labeling or providing
supplemental information to the labeling regarding the use of
the identified drug, including--
(A) data from randomized controlled trials
demonstrating reduced effectiveness or safety changes
of approved oncology products for patients with
specific actionable genetic alterations;
(B) prospective or retrospective biomarker analyses
from adequate and well-controlled studies;
(C) real-world evidence; and
(D) mechanistic or preclinical evidence in
conjunction with clinical data, where appropriate; and
(3) with consideration given to--
(A) whether a companion diagnostic test approved or
cleared under section 515 or section 510(k) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e
and 21 U.S.C. 360(k)) respectively, or a laboratory
developed test, is necessary to identify patients with
a relevant actionable genetic alteration prior to
seeking or initiating a labeling change to incorporate
a genomic exclusion criterion into labeling under
subsection (b);
(B) promoting alignment, in coordination with the
Center for Devices and Radiological Health, as
appropriate, between revised oncology drug labeling
under this section and the labeling of approved or
cleared companion diagnostics; and
(C) utilization of genomic profiling under next-
generation sequencing or other multi-gene testing as a
basis for identifying patients subject to a genomic
exclusion criterion.
(d) Expedited Review for Labeling Supplements.--Labeling
supplements to incorporate genomic exclusion criteria submitted
pursuant to 505(xx) or 505(o)(4) shall--
(1) be exempt from user fees under the Prescription Drug
User Fee Act; and
(2) be reviewed and acted upon no later than 180 days after
submission of a complete supplement.
Nothing in this subsection shall be constructed to limit the processes
outlined in 505(o)(4).
(e) Transparency and Public Access.--The Secretary shall--
(1) maintain and make publicly available on the Food and
Drug Administration's website a registry of oncology drug
labels updated under the Program, and the evidence basis for
each genomic exclusion determination; and
(2) publish, not less frequently than annually, a report
summarizing Program activities, labeling updates completed,
supplements received and acted upon, and any anticipated
genetic alterations under consideration for the following year;
(f) Guidance.--Within 180 days of enactment of the Precision
Oncology Modernization Act, the Secretary shall issue draft guidance on
the actions described in subsection (b), standards in subsection (c),
and role of the CDRH outlined in subsection (d). The guidance shall be
finalized no later than 2 years after enactment.
(g) Report to Congress.--Not later than 3 years after the date of
enactment of this Act, and every 2 years thereafter, the Secretary
shall submit to the Committee on Energy and Commerce of the House of
Representatives and the Committee on Health, Education, Labor, and
Pensions of the Senate a report that includes--
(1) a description of the activities carried out under the
Program, including the number of oncology drug labels reviewed,
updated, or pending update;
(2) the number of voluntary labeling supplements received
and acted upon under the Program;
(3) an assessment of challenges and barriers encountered in
implementing the Program, including any scientific, legal, or
operational barriers;
(4) recommendations for legislative or regulatory changes
that would improve the Program or accelerate the incorporation
of genomic exclusion criteria into oncology drug labeling; and
(5) an analysis of the potential impact of Program
activities on patient outcomes, treatment sequencing, and
access to targeted oncology therapies.
(h) Rule of Construction.--Nothing in this Act shall be construed--
(1) to limit the authority of the Secretary to require
labeling changes for approved drugs under any other provision
of the Federal Food, Drug, and Cosmetic Act or the Public
Health Service Act; and
(2) to affect the approval status of any oncology drug or
biological product approved before the date of enactment of
this Act except with respect to labeling updates made pursuant
to the Program.
The rules of construction under section 503D(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 353d(b)) shall be deemed to apply to
this section.
(i) Definitions.--In this Act:
(1) Actionable genetic alteration.--The term ``actionable
genetic alteration'' means a somatic or germline mutation, gene
fusion, copy number variation, or other molecular aberration in
a patient's tumor or germline that has been demonstrated
through clinical evidence to predict a meaningful difference in
response or resistance that impacts the safety or efficacy of a
drug or biological product intended to treat cancer.
(2) Approved targeted oncology therapy.--The term
``approved targeted oncology therapy'' means a drug or
biological product approved under section 505 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of
the Public Health Service Act (42 U.S.C. 262) for the treatment
of a cancer defined in whole or in part by the presence of a
specific genetic alteration.
(3) Genomic exclusion criterion.--The term ``genomic
exclusion criterion'' means a labeling statement specifying
that a drug is not indicated for, or should not be used in,
patients whose tumors harbor a specific actionable genetic
alteration for which an alternative approved targeted oncology
therapy exists.
TITLE V--AMERICAN FRONTIER BIOBANK
SEC. 501. ESTABLISHMENT OF THE AMERICAN FRONTIER BIOBANK.
(a) In General.--Part A of title IV of the Public Health Service
Act (42 U.S.C. 281et seq.) is amended by adding at the end following:
``SEC. 404P. AMERICAN FRONTIER BIOBANK.
``(a) In General.--Pursuant to section 498E, the Director of NIH
shall carry out a program to be known as the `American Frontier Biobank
Program' (referred to in this section as the `Biobank Program'), which
shall expand upon the work of the All of Us Research Program.
``(b) Transition.--Not later than 6 months after the date of the
enactment of this section, the Director of NIH shall--
``(1) transfer to the Biobank Program, the authorities
(including all budget authorities, available appropriations,
and personnel), duties, obligations, and related legal and
administrative functions, and the existing cohort, data,
computational infrastructure, and biobanking capabilities of
the All of Us Research Program; and
``(2) provide for the orderly transition or realignment of
awards made under, and capabilities of, the All of Us Research
Program.
``(c) Administrator.--The Biobank Program shall be headed by an
Administrator appointed by the Director of NIH. Such person shall be
known and referred to as the American Frontier Biobank Administrator
(in this section referred to as the `Administrator').
``(d) Program Elements.--In carrying out the Biobank Program, the
Administrator shall--
``(1) make awards to, or enter into contracts with,
corporate entities or nonprofit entities across the United
States to facilitate--
``(A) the collection, storage, molecular data
generation, and analysis of biological specimens,
including longitudinal molecular and clinical data; and
``(B) with the support of artificial intelligence
and other technologies, as appropriate, incorporating
electronic health records of participants in accordance
with subsection (c);
``(2) facilitate the recruitment of participants that are
representative of at least 3 percent of the United States
population, including representation of each State of the
United States, the District of Columbia, each commonwealth,
territory or possession of the United States, and each
federally recognized Indian Tribe, with longitudinal data
gathered in both urban and rural populations, including a
pediatric cohort of participants;
``(3) in facilitating the recruitment of participants under
paragraph (2) who are members of a federally recognized Indian
Tribe, work in partnership with Tribal nations, and through
Tribal consultation, to establish mutually agreeable terms for
Tribal participation, and operational processes and oversight,
that respect Tribal sovereignty;
``(4) enter into data sharing agreements with private and
nonprofit entities to build upon existing processes for the
rapid, cost-effective, and scalable recruitment, and enrollment
of, and obtaining informed consent from, participants for the
collection of longitudinal data;
``(5) seek to enroll in clinical trials, using data in the
Biobank, the individuals whose biological specimens are stored
in the Biobank;
``(6) share deidentified data collected for the Biobank
Program with all registered researchers;
``(7) incorporate existing data sources of the National
Institutes of Health, and other relevant datasets (as
determined by the Administrator) into research activities
conducted through the Biobank Program, including data collected
through the All of Us initiative and the Department of Veterans
Affairs Millions Veterans Program;
``(8) generate and integrate multi-modal data, including
genomic, proteomic, metabolomic, and other molecular data, with
electronic health records and participant-reported information;
``(9) enable longitudinal participant data collection,
including by conducting repeat sampling, engaging in continuous
health data integration, and developing scalable research
infrastructure to reduce the long-term costs of biomedical
research and health care innovation;
``(10) support artificial intelligence-ready
infrastructure, including secure, federated data systems that
enable large-scale analysis while deidentifying patient data;
``(11) facilitate the translation of research findings into
clinical applications, including mechanisms for public and
private funding to support Biobank Program activities; and
``(12) carry out all other activities as determined by the
advisory board for the Biobank.
``(e) Advisory Board.--The Director of NIH shall establish a
national advisory board to oversee the functions of the Biobank. The
advisory board shall include representatives from--
``(1) the Institutes and Centers of the National Institutes
of Health;
``(2) other relevant Federal agencies;
``(3) public and private research institutions, including
entities that performed key participant and community
engagement, genomic sequencing, and data security functions of
the All of Us Research Program;
``(4) health care systems;
``(5) artificial intelligence and data experts;
``(6) clinical trial design experts;
``(7) pharmaceutical, biologic, and medical technology
companies; and
``(8) experts in the ethical, legal, and social
implications of science and technology.
``(f) Multi-Modal Data.--The data described in subsection (c)(7)
may link biological, clinical, environmental, and other data, including
information related to environmental exposures and factors identified
using a life course approach.
``(g) Privacy Protections and Informed Consent.--
``(1) In general.--The Director of NIH shall ensure that
any entity collecting data or specimens from any individual
through the Biobank Program or conducting any clinical trial
using such data or specimens, or in any other way using such
data or specimens--
``(A) collects biospecimens and associated clinical
and demographic information only from participants who
have given their informed consent in accordance with
Federal and State law; and
``(B) protects personal privacy to the extent
required by applicable Federal and State law, at
minimum.
``(2) Informed consent.--The Director of NIH shall continue
to ensure that all biospecimens and associated clinical and
other demographic information are collected with the informed
consent and authorization of individuals participating in the
Biobank Program, or their legally authorized representative, in
accordance with the law.
``(h) Congressional Notification.--Not later than one year after
the date of the enactment of this section, and annually thereafter, the
Director of NIH shall submit to the appropriate congressional
committees a notification on all activities as determined by the
advisory board for the Biobank.
``(i) Authorization of Appropriations.--For purposes of carrying
out this section, there is authorized to be appropriated $500,000,000
for fiscal year 2027 and each subsequent fiscal year, to remain
available until expended.''.
(b) Roadmap.--Not later than 180 days after the date of the
enactment of this Act, the Director of NIH shall submit to Congress, in
consultation with relevant public and private entities on the advisory
board, a roadmap for implementation and augmentation of the Biobank
Program established under section 404P of the Public Health Service
Act, as added by subsection (a), including scientific priorities, an
infrastructure development plan, a public-private partnership financing
strategy, and a budget for 5 fiscal years.
<all>